Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Retina ; 38(6): 1079-1083, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28471890

RESUMEN

PURPOSE: Fibrovascular contraction and tractional retinal detachment (TRD) are recognized complications associated with the use of anti-vascular endothelial growth factor agents in vasoproliferative vitreoretinopathies. The authors characterize TRDs that developed after intravitreal bevacizumab or ranibizumab therapy for vascularly active retinopathy of prematurity. METHODS: This is an international, multicenter, interventional, retrospective, case series. Thirty-five eyes from 23 infants were included. Inclusion required anti-vascular endothelial growth factor treatment of Type 1 retinopathy of prematurity with progression to TRD. RESULTS: Mean gestational age was 26 ± 2 weeks, and mean birth weight was 873 ± 341 g. Mean postmenstrual age on the day of injection was 35 ± 2 weeks. Retinal detachment was noted a mean of 70 days (median, 34; range, 4-335) after injection. Eleven percent detached within 1 week, 23% within 2 weeks, and 49% within 4 weeks. The highest stage of retinopathy of prematurity noted was 4A in 29%, 4B in 37%, and 5 in 34% of eyes. Time to RD negatively correlated with postmenstrual age at the time of injection (Rho = -0.54; P < 0.01). Three TRD configurations were observed: 1) conventional peripheral elevated ridge or volcano-shaped Stage 5 detachment, 2) midperipheral detachment with tight circumferential vectors, and 3) very posterior detachment with prepapillary contraction. Full or partial reattachment was achieved with surgical intervention in 86% of eyes. CONCLUSION: Progressive atypical TRD may occur after anti-vascular endothelial growth factor injections for retinopathy of prematurity. The configuration of the detachment varies with the extent of primary retinal vascularization present at the time of treatment.


Asunto(s)
Inhibidores de la Angiogénesis/efectos adversos , Bevacizumab/efectos adversos , Ranibizumab/efectos adversos , Desprendimiento de Retina/inducido químicamente , Retinopatía de la Prematuridad/tratamiento farmacológico , Inhibidores de la Angiogénesis/administración & dosificación , Inhibidores de la Angiogénesis/uso terapéutico , Bevacizumab/administración & dosificación , Bevacizumab/uso terapéutico , Femenino , Humanos , Lactante , Recién Nacido , Inyecciones Intravítreas , Masculino , Ranibizumab/administración & dosificación , Ranibizumab/uso terapéutico , Estudios Retrospectivos
2.
Community Eye Health ; 30(99): 60-61, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29434441
3.
Digit J Ophthalmol ; 25(4): 49-58, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32076388

RESUMEN

Retinopathy of prematurity (ROP) is one of the leading causes of preventable blindness in children worldwide. Middle-income nations are currently experiencing epidemic levels of ROP, because greater access to neonatal intensive care units has improved survival rates of premature infants, but without sophisticated oxygen regulation. The epidemiology, screening infrastructure, treatment options, and challenges that these countries face are often tied to unique local socioeconomic, cultural, geopolitical, and medical factors. We present an overview and narratives of the current state of ROP in eight countries that are or soon will be experiencing ROP epidemics-India, Kenya, Mexico, Nigeria, Phillipines, Romania, Thailand, and Venezuela-with a view to fostering both an understanding of the differences in the ROP landscape in various settings and an interest in the further development of ROP screening and treatment services tailored to local requirements.


Asunto(s)
Ceguera/etiología , Recien Nacido Prematuro , Retinopatía de la Prematuridad/etnología , Ceguera/epidemiología , Humanos , Incidencia , India/epidemiología , Recién Nacido , Unidades de Cuidado Intensivo Neonatal/estadística & datos numéricos , Kenia/epidemiología , México/epidemiología , Nigeria/epidemiología , Filipinas/epidemiología , Prevalencia , Retinopatía de la Prematuridad/complicaciones , Rumanía/epidemiología , Tailandia/epidemiología , Venezuela/epidemiología
4.
Oftalmologia ; 50(4): 33-8, 2006.
Artículo en Ro | MEDLINE | ID: mdl-17345800

RESUMEN

INTRODUCTION: Fungal keratitis is one of the most difficult corneal infections to be properly diagnosed and treated. PURPOSE: Diagnostic and therapeutic approaches in atypical keratitis, regarding a case. MATERIAL AND METHOD: The paper presents a case of stromal fungal keratitis successfully treated with topical amphotericin B 0,2% and natamycin 5%. The clinical appearance and the indolent course directed the diagnosis, the micro-biological analysis of corneal scrapings being negative. Further on, there are presented the laboratory investigations and the available antifungal agents, because proper therapy early in the course of the disease can be crucial to a successful outcome. CONCLUSIONS: Clinical suspicion of fungal keratitis is essential to diagnosis, but once the diagnosis is made, the treatment remains difficult. Direct microscopic examination of corneal tissues using specific stains is a very useful and inexpensive method of diagnosis, being conclusive in 80% of cases.


Asunto(s)
Antifúngicos/administración & dosificación , Infecciones Fúngicas del Ojo/diagnóstico , Infecciones Fúngicas del Ojo/tratamiento farmacológico , Queratitis/diagnóstico , Queratitis/tratamiento farmacológico , Adulto , Anfotericina B/administración & dosificación , Quimioterapia Combinada , Infecciones Fúngicas del Ojo/microbiología , Femenino , Humanos , Queratitis/microbiología , Microscopía Acústica , Natamicina/administración & dosificación , Soluciones Oftálmicas/administración & dosificación , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda